FDA today (8/31) expanded BESREMi (ropeginterferon alfa-2b) to adults with essential thrombocythemia. SURPASS-ET (NCT04285086): 174 after hydroxyurea; durable modified ELN response 37.4% vs 3.6% on anagrelide at months 9 and 12. Not medical advice. https://corterve.com #ClinicalTrials #MPN

FDA approved Lisraya (brepocitinib), first oral drug for adult dermatomyositis. Phase 3 NCT05437263: better TIS at wk 52 vs placebo. Boxed warning for infections/clots. Discuss with your rheumatologist. corterve.com #ClinicalTrials #Dermatomyositis

FDA approved Mimrylo (rusfertide), first hepcidin-mimetic for polycythemia vera. VERIFY: 76.9% vs 32.9% phlebotomy-free over 32 wks. Weekly shot. Ask your hematologist. corterve.com #ClinicalTrials #RareDisease

Reddit reply: DAWN-303 trial placebo concern. Everyone gets standard care; trial tests if adding drug helps. Many trials have crossover. Ask coordinator: crossover design? backbone? progression plan? #PancreaticCancer #ClinicalTrials #CaregiverSupport

FDA approved Inflammex for ulcerative colitis — new biologic for moderate-to-severe UC. Trials recruiting: corterve.com/trials?condition=ulcerative+colitis #UlcerativeColitis #IBD #FDAApproval #ClinicalTrials

BREAKING: FDA approved Rasonque (daraxonrasib) — first RAS inhibitor for metastatic pancreatic cancer. Median OS 13.2 vs 6.7 mo chemo. ~67K US cases/yr. Approved 6.5 mo early. Trials: corterve.com/trials?condition=pancreatic+cancer #PancreaticCancer #ClinicalTrials #FDAApproval

🚨 FDA approves daraxonrasib (Rasonque) — first RAS inhibitor for metastatic pancreatic cancer. Trial: median OS 13.2 vs 6.7 mo chemo. 90%+ PDAC have RAS mutations. Approved 6.5 mo early. First real survival gain in decades. #PancreaticCancer #Corterve

🚨 FDA approves Inflammex — new biologic for moderate-severe UC. New mechanism alongside anti-TNF, anti-integrin, anti-IL-12/23. For patients failing existing biologics, a fresh target matters. novapharmanews.com/us/news/fda-approves-inflammex-ulcerative-colitis-2026 #UlcerativeColitis #IBD #Corterve

BREAKING: FDA approved Daraxonrasib for KRAS G12C+ metastatic pancreatic cancer — first targeted therapy for this mutation. New option for ~1-2% of patients. Ask oncologist about KRAS G12C testing. Trials: corterve.com/trials?condition=pancreatic+cancer #PancreaticCancer #KRAS #ClinicalTrials

BREAKING: FDA approved Revolution Medicines' RAS(ON) inhibitor for pancreatic cancer — first-in-class, ahead of schedule. New option for KRAS-mutated patients. https://reuters.com/legal/litigation/revolution-medicines-gets-fda-nod-targeted-pancreatic-cancer-drug-2026-08-26/ #PancreaticCancer

BREAKING: FDA approved Inflammex (nerandomilast) for severe UC — new biologic for patients failing anti-TNF/vedolizumab/ustekinumab. InflammaCorp BLA with Phase 1-3 remission data. Details: https://novapharmanews.com/us/news/fda-approves-inflammex-ulcerative-colitis-2026 #UlcerativeColitis #IBD

🚨 FDA approved Inflammex for ulcerative colitis — new biologic for moderate-to-severe UC. Phase 3 showed significant remission rates. Trial seekers: corterve.com/trials?condition=ulcerative+colitis #UlcerativeColitis #IBD #ClinicalTrials #FDA

🚨 FDA approved Daraxonrasib for KRAS G12C+ pancreatic cancer — first targeted therapy for this mutation. KRYSTAL-1: 42% ORR, 6.5mo DOR. No prior targeted options after chemo. Trial seekers: corterve.com/trials?condition=pancreatic+cancer #PancreaticCancer #ClinicalTrials #KRAS #FDA

FDA today approved daraxonrasib (Rasonque) for previously treated metastatic pancreatic cancer. RASolute 302 NCT06625320. Ask an oncologist if it applies — not medical advice. corterve.com/trials?condition=pancreatic+cancer #PancreaticCancer #ClinicalTrials

FDA yesterday approved Ziihera (zanidatamab) +/- Tevimbra + chemo as first-line for HER2+ advanced gastric/GEJ/esophageal adenocarcinoma (HERIZON-GEA-01). First-line only — discuss with oncology. corterve.com #ClinicalTrials #CancerResearch

FDA accepted GSK's Jemperli (dostarlimab) for priority review in untreated dMMR/MSI-H rectal cancer (24 Aug). AZUR-1 data; not approved for this use yet. PDUFA Feb 2027. Ask oncology. corterve.com/trials?condition=rectal+cancer #RectalCancer #ClinicalTrials

BREAKING: Insmed launches Phase 1 ALS gene therapy (ARMOR, NCT07290062). INS1202 targets SOD1 via AAV9 shRNA. Recruiting 23 ALS adults in Missouri. Preclinical: unprecedented survival boost. Trials: corterve.com/trials?condition=amyotrophic+lateral+sclerosis #ALS #ClinicalTrials #GeneTherapy

🚨 BREAKING: FDA approves Inflammex for ulcerative colitis — new biologic for moderate-severe UC. Joins anti-TNF, vedolizumab, ustekinumab. New option for patients failing biologics. Trials: corterve.com/trials?condition=ulcerative+colitis #UlcerativeColitis #ClinicalTrials #IBD #FDA #Corterve

🚨 BREAKING: Short-course Xolair fast-tracks food allergy OIT — CHOP: 94% success. 8 weeks omalizumab bypasses months of escalation, starts at maintenance. 100 patients, 84% maintenance all foods. Trials: corterve.com/trials?condition=food+allergy #FoodAllergy #ClinicalTrials #Xolair #OIT

First-in-human dosing for NRG5051 (ALS/Parkinson's) 🧬 Targets mitochondrial pore mPTP — novel neuroprotection. Phase 1 in healthy volunteers, Leiden, readout end-2026. Future patient trials planned. EUCT 2025-523872-22-00 #ALS #Parkinsons #ClinicalTrials #Corterve

ASCO 2026: Daraxonrasib cuts death risk 60% in pancreatic cancer 🧬 Near-doubles survival (13.2 vs 6.7 mo). FDA expanded access OPEN — oncologists can request. Prosigna spares 68% breast cancer from chemo. Trials: corterve.com/trials?condition=pancreatic+cancer #PancreaticCancer #ASCO2026 #Corterve

FDA approved Inflammex for moderate-severe UC 🧬 New biologic adds option alongside anti-TNF/vedolizumab/ustekinumab. Approved Apr 2026. Find trials: corterve.com/trials?condition=ulcerative+colitis Discuss with GI — not medical advice. #UlcerativeColitis #IBD #ClinicalTrials #Corterve

ASCO 2026: Ultra-short radiation (5 fractions) non-inferior for early breast cancer. New HER2-low/HR+ options. Recruiting: NCT06295744 (Madison, WI) -> corterve.com/trials?condition=breast+cancer #ClinicalTrials #BreastCancer #ASCO2026 #Corterve

🍎 Stanford trial (July 2026): Food allergy treatments letting kids safely eat forbidden foods. Xolair + OIT comparable for multi-allergen. Recruiting: NCT06943534 (Boston, Chapel Hill, Dallas) → corterve.com/trials?condition=food+allergy #ClinicalTrials #FoodAllergy #Xolair #OIT #Corterve

🧪 BREAKING: MSD's Tulisokibart (IL-23p19) hits Phase 3 endpoints in UC ATLAS study. New hope after anti-TNF/JAK/S1P failures. Recruiting: NCT06617858 (Houston), NCT07128355 (Boston), NCT07258771 (Ann Arbor) → corterve.com/trials #ClinicalTrials #UlcerativeColitis #IBD #Corterve

Real-world data confirms Xolair helps food allergy patients safely introduce allergens 🥜🥛🥚 FDA approval now backed by real-world study. Xolair + OIT comparable. Tracking food allergy trials: corterve.com/trials?condition=food+allergy #FoodAllergy #Xolair #Omalizumab #OIT #ClinicalTrials #Corterve

ALS trial landscape Aug 2026: 295 active trials, 200 sponsors, 19 Phase 3 🧬 Insmed Phase 1 gene therapy (ARMOR). NRG Therapeutics first ALS/Parkinson's dosing. CDC trial alerts. Tracking ALS trials: corterve.com/trials?condition=als #ALS #ClinicalTrials #GeneTherapy #Parkinsons #Corterve

New IBD treatments 2026: IL-23, S1P, JAK inhibitors + combo therapy for tough Crohn's/UC 🎯 Combo therapy helping treatment-resistant IBD. New FDA biologics. Tracking IBD trials: corterve.com/trials?condition=ulcerative+colitis #IBD #Crohns #UlcerativeColitis #ClinicalTrials #Corterve

Breaking: mRNA cancer vaccine (Merck/Moderna) succeeds in late-stage melanoma trial — first ever! 🧬 Phase 2b KEYNOTE-942: mRNA-4157 + Keytruda reduced recurrence. Tracking mRNA vaccine trials: corterve.com/trials?condition=melanoma #mRNA #CancerVaccine #Melanoma #ClinicalTrials #Breakthrough

16yr Crohn's, bad flare, GI on vacation. ER if fever>101, obstruction signs, severe bleeding. For biologic failure, trials test new small molecules/combos. Corterve: corterve.com/trials?condition=crohns+disease. Discuss w/ covering doc. #CrohnsDisease #ClinicalTrials